Coca-Cola European Partners PLC (CCEP)vsVertex Pharmaceuticals Inc (VRTX)
CCEP
Coca-Cola European Partners PLC
$93.23
+1.06%
CONSUMER DEFENSIVE · Cap: $41.69B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Coca-Cola European Partners PLC generates 74% more annual revenue ($20.90B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs 9.3%. VRTX appears more attractively valued with a PEG of 2.19. VRTX earns a higher WallStSmart Score of 66/100 (B-).
CCEP
Buy59
out of 100
Grade: C
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+57.7%
Fair Value
$230.72
Current Price
$93.23
$137.49 discount
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 68.3% YoY
Every $100 of equity generates 23 in profit
Generating 1.5B in free cash flow
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.2% revenue growth
Distress zone — elevated risk
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CCEP
The strongest argument for CCEP centers on EPS Growth, Return on Equity, Free Cash Flow.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : CCEP
The primary concerns for CCEP are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CCEP profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
CCEP carries more volatility with a beta of 0.39 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
CCEP generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 59/100), backed by strong 32.9% margins. CCEP offers better value entry with a 57.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coca-Cola European Partners PLC
CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA
Coca-Cola Europacific Partners PLC produces, distributes and sells a variety of ready-to-drink non-alcoholic beverages. The company is headquartered in Uxbridge, the United Kingdom.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BEVERAGES - NON-ALCOHOLIC Stocks
Want to dig deeper into these stocks?